MENU
Now in various stages of clinical development, the programs in our pipeline are focused on autoinflammatory and autoimmune diseases with unmet needs, and have the potential to address multiple therapeutic areas.
| Program & Target | Therapeutic Area | Preclinical | Phase 1 | Phase 2 | Phase 3 | Mkt | Rights | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Rilonacept IL-1α & IL-1β | Recurrent pericarditis (breakthrough therapy designation) |
Mid Phase 3 | Worldwide (excluding the Middle East and North Africa) | |||||||
| Mavrilimumab GM-CSFRα | Giant cell arteritis | Phase 2 | Worldwide | |||||||
| Relapsed or refractory |
End Phase 1 | Worldwide | ||||||||
| KPL-716 OSMRβ | Prurigo nodularis | Phase 2 | Worldwide | |||||||
| Multi-indication pilot study in diseases with a chronic pruritic component | Phase 2 | Worldwide | ||||||||
| KPL-404 CD40 | T-cell dependent, B-cell–mediated indications | Phase 1 | Worldwide | |||||||
